{
    "clinical_study": {
        "@rank": "26924", 
        "arm_group": [
            {
                "arm_group_label": "Luveris", 
                "arm_group_type": "Active Comparator", 
                "description": "Evaluation the effect of Luveris protocol on Induction of ovulation in Patients with Hypogonadotropic Hypogonadism"
            }, 
            {
                "arm_group_label": "Gonal-F& Luveris", 
                "arm_group_type": "Active Comparator", 
                "description": "Evaluation the effect of Gonal-F& Luveris protocols of Induction of ovulation in Patients with Hypogonadotropic Hypogonadism"
            }
        ], 
        "brief_summary": {
            "textblock": "We wanted to compare the Assisted Reproductive Technology (ART) outcomes between two\n      protocols of induction of ovulation in patients with Hypogonadotropic Hypogonadism. In the\n      beginning, all patients receive Recombinant Follicle Stimulating Hormone (Gonal-F) and\n      Recombinant Luteinizing Hormone (Luveris). When at least one follicle reaches 14 mm in\n      diameter, Luveris alone is administered for group A and both drugs Gonal-F and Luveris for\n      group B. Finally Assisted Reproductive Technology (ART) results are compared between the two\n      groups."
        }, 
        "brief_title": "Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": [
                "Hypogonadism", 
                "Infertility"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this single blind randomized clinical trial, 90 women with a clinical history of\n      hypogonadotrophic hypogonadism who stopped any treatment with gonadotrophins >1 month before\n      study, with a negative progesterone challenge test, low serum gonadotrophins (Luteinizing\n      Hormone (LH) and Follicle Stimulating Hormone (FSH) less than 5.0 IU/l) and oestradiol (less\n      than 100 pg/ml) and normal serum concentrations of thyroid stimulating hormone (TSH),\n      testosterone and prolactin within 6 months before the start of treatment are studied in the\n      Royan Institute. Other causes of infertility are excluded from the study. All patients\n      receive treatment with recombinant follicle stimulating hormone (Gonal-F) and recombinant\n      luteinizing hormone (Luveris). When at least one follicle reaches 14 mm in diameter, 4mg/day\n      oestradiol is administered and patients are randomly divided into two groups: Luveris alone\n      (intervention group) and continued treatment with both drugs Gonal-F and Luveris (control\n      group). When at least one follicle detects a mean diameter of \u226518 mm and serum estradiol\n      level reaches 500-2000 pg/ml, ovarian stimulation is stopped and injection of 10000 IU Human\n      Chorionic Gonadotrophin (hCG) is administrated.\n\n      At the end, the number and size of ovarian follicles, endometrial thickness on the day of\n      injection of Human Chorionic Gonadotrophin (hCG), the number of oocytes retrieved, the\n      number of good quality embryos, chemical and clinical pregnancy rate, fertilization rate and\n      implantation rate will be compared between the two groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a clinical history of hypogonadotropic hypogonadism, and laboratory test result\n             comply with diagnosis of hypogonadotropic hypogonadism\n\n          -  Have discontinued gonadotropins or gonadotropin releasing hormone or\n             estrogen-progesterone replacement therapy at least one month before the study\n\n          -  Have primary or secondary amenorrhea\n\n          -  Serum Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) <5.0 IU/l and\n             oestradiol <100 pg/ml before initiation of treatment\n\n          -  Have a negative progesterone challenge test\n\n          -  Normal serum concentrations of thyroid stimulating hormone (TSH), prolactin and\n             testosterone within 6 months before the start of study\n\n          -  Be willing and able to comply with the protocol for the duration of the study\n\n          -  Have given written informed consent prior to any study related procedure\n\n        Exclusion Criteria:\n\n          -  The other causes of infertility.\n\n          -  History of ovarian hyper stimulation syndrome\n\n          -  Abnormal gynecological bleeding of undetermined origin\n\n          -  Previous or current hormone dependent tumor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140515", 
            "org_study_id": "royan-Emb-018"
        }, 
        "intervention": [
            {
                "arm_group_label": "Luveris", 
                "description": "Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)", 
                "intervention_name": "Lutropin alfa", 
                "intervention_type": "Drug", 
                "other_name": "Follitropin alfa: Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)"
            }, 
            {
                "arm_group_label": "Gonal-F& Luveris", 
                "description": "Administration of  (rFSH) and  (rLH)", 
                "intervention_name": "Follitropin alfa and Lutropin alfa", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Follitropin alfa: Gonal-F or recombinant Follicle Stimulating Hormone (rFSH) and", 
                    "Lutropin alfa: Luveris or Recombinant Luteinizing Hormone (rLH)"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Follicle Stimulating Hormone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Gonal-F  Luveris Assisted Reproductive Technology  Hypogonadotropic Hypogonadism", 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "url": "http://Royaninstitute.org"
        }, 
        "location": {
            "contact": {
                "email": "nasser.aghdami@royaninstitute.org", 
                "last_name": "Nasser Aghdami, MD,PhD", 
                "phone": "(+98)2123562000", 
                "phone_ext": "516"
            }, 
            "contact_backup": {
                "email": "Leara91@gmail.com", 
                "last_name": "Leila Arab, m", 
                "phone": "(+98)23562000", 
                "phone_ext": "414"
            }, 
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Royan Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Reza Khalili, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jhaleh Etminan, Bsc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "sdamaneh Jalali, BSc", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation by Using Recombinant Luteinizing Hormone (rLH) and Recombinant Follicle Stimulating Hormone (rFSH) in Patients With Hypogonadotropic Hypogonadism", 
        "overall_contact": {
            "email": "nasser.aghdami@royaninstitute.org", 
            "last_name": "Nasser Aghdami, MD,PhD", 
            "phone": "(+98)2123562000", 
            "phone_ext": "516"
        }, 
        "overall_contact_backup": {
            "email": "Leara91@gmail.com", 
            "last_name": "Leila Arab, MD", 
            "phone": "(+98)2123562000", 
            "phone_ext": "414"
        }, 
        "overall_official": [
            {
                "affiliation": "Head of Royan Institute", 
                "last_name": "Hamid Gourabi, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.", 
                "last_name": "Tahereh Madani, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Department of Endocrinology and Female Infertility, Reproductive Biomedicine Research Centre, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran", 
                "last_name": "Seyedeh Masoumeh Moosavi Sadat, MSc", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Iran: Ethics Committee", 
                "Iran: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Evaluation thre number follicles before injection of Human Chorionic Gonadotrophin (hCG)", 
                "measure": "number of follicles", 
                "safety_issue": "Yes", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Evaluation the size of follicle before injection of Human Chorionic Gonadotrophin (hCG)", 
                "measure": "Size of follicle", 
                "safety_issue": "Yes", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Evaluation the endometrial thickness at the day of injection of Human Chorionic Gonadotrophin (hCG)", 
                "measure": "Endometrial thickness", 
                "safety_issue": "Yes", 
                "time_frame": "1day"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140515"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluation the number of oocytes retrieved 34-36 hours after Human Chorionic Gonadotrophin (hCG) injection", 
                "measure": "number of oocytes retrieved", 
                "safety_issue": "Yes", 
                "time_frame": "3 days"
            }, 
            {
                "description": "Evaluation the fertilization rate  2-3 days before the embryo transfer", 
                "measure": "Fertilization rate", 
                "safety_issue": "Yes", 
                "time_frame": "2 days"
            }, 
            {
                "description": "Evaluation the biochemical pregnancy rate 2 weeks after embryo transfer", 
                "measure": "Biochemical pregnancy rate", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "Evaluation the clinical pregnancy rate 4-6 weeks after embryo transfer", 
                "measure": "Clinical pregnancy rate", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Evaluation the implantation rate 4-6 weeks after embryo transfer.", 
                "measure": "Implantation rate", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Royan Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Royan Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}